Key result
In 120 lean women with PCOS, lipid accumulation product and visceral adiposity index were significantly higher in the 39 insulin-resistant subjects compared to those without insulin resistance.
Why the study?
Do lipid accumulation product (LAP) and visceral adiposity index (VAI) correlate with clinical, hormonal, and metabolic parameters in lean women with PCOS?
Observational (n=120)
Do lipid accumulation product (LAP) and visceral adiposity index (VAI) correlate with clinical, hormonal, and metabolic parameters in lean women with PCOS?
LAP and VAI are promising markers for the early identification of insulin resistance and cardiometabolic risk in lean women with PCOS.
May aid early IR detection in lean PCOS; hypothesis-generating and requires prospective validation before clinical use.
This study was performed to assess the impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal, and metabolic parameters in lean women with PCOS. Retrospective analysis of 120 consecutive lean PCOS subjects was performed. Subjects were divided into two groups according to HOMA-IR, as IR + and IR-. A HOMA-IR value above 2.5 was used to indicate IR. Clinical, hormonal and metabolic parameters were compared between the two groups. Correlations between LAP and VAI and clinical, hormonal, metabolic features in women PCOS were analyzed. One hundred twenty lean PCOS subjects were enrolled, of which 39 were insulin resistant. Comparison of group means showed significantly higher values for TG levels, FAI, FGS, TG/HDL-c, TyG, LAP, and VAI indexes and lower values for glucose/insulin ratio and QUICKI in the IR + group. LAP and VAI were both found to be positively correlated with each other and with WC, FAI, FGS, TG, TC levels, lipid ratios, TyG index, and HOMA-IR and negatively correlated with Glucose/Insulin ratio, QUICKI, and HDL-c in lean women with PCOS. LAP and VAI may be promising in early identification of IR and cardiometabolic risk and may be useful for the assessment of hyperandrogenism in lean women with PCOS.
No takes yet. Share an insight, caveat, or question.
İlhan et al. (2018) conducted an observational in Polycystic ovary syndrome (n=120). Insulin resistance (HOMA-IR > 2.5) vs. No insulin resistance (HOMA-IR ≤ 2.5) was evaluated on Clinical, hormonal and metabolic parameters including LAP and VAI. In 120 lean women with PCOS, lipid accumulation product and visceral adiposity index were significantly higher in the 39 insulin-resistant subjects compared to those without insulin resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: